Update: Moving beyond antibodies
MorphoSys’s acquisition of Lanthio Pharma adds a promising product due to enter Phase I in 2016 and diversifies its portfolio beyond antibodies. The lead product MOR107 is being developed for nephropathy and fibrosis; large indications with limited treatment options available. MOR107 is also a lanthipeptide, which promises to combine the benefits of monoclonal antibodies and small molecules. The acquisition also positions MorphoSys as a leader in the field of peptide therapeutics.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.